{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:11:43Z","timestamp":1740107503210,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["(JP21fk0310103","JP21fk0210053","JP21fk0210072","JP20fk0210056","JP21fk0310101","JP21fk0210047","JP21fk0210064","JP21fk0210056","JP21fk0210048","JP21fk0210058","JP21fk0210066","21fk0210067"],"award-info":[{"award-number":["(JP21fk0310103","JP21fk0210053","JP21fk0210072","JP20fk0210056","JP21fk0310101","JP21fk0210047","JP21fk0210064","JP21fk0210056","JP21fk0210048","JP21fk0210058","JP21fk0210066","21fk0210067"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K08371","JP22K15954"],"award-info":[{"award-number":["JP20K08371","JP22K15954"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00535-023-01993-w","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T10:02:06Z","timestamp":1682589726000},"page":"656-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4860-1353","authenticated-orcid":false,"given":"Masato","family":"Nakai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risako","family":"Kohya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonoe","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Tokuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kitagataya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Sho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-059X","authenticated-orcid":false,"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"1993_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406\u201360.","journal-title":"J Hepatol"},{"key":"1993_CR2","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/hep.31884","volume":"74","author":"SW Biggins","year":"2021","unstructured":"Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases. Hepatology. 2021;74:1014\u201348.","journal-title":"Hepatology"},{"key":"1993_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","volume":"56","author":"H Yoshiji","year":"2021","unstructured":"Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. J Gastroenterol. 2021;56:593\u2013619.","journal-title":"J Gastroenterol"},{"key":"1993_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/hepr.13678","volume":"51","author":"H Yoshiji","year":"2021","unstructured":"Yoshiji H, Nagoshi S, Akahane T, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res. 2021;51:725\u201349.","journal-title":"Hepatol Res"},{"key":"1993_CR5","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/jcsm.12797","volume":"12","author":"X Zeng","year":"2021","unstructured":"Zeng X, Shi ZW, Yu JJ, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. J Cachexia Sarcopenia Muscle. 2021;12:1948\u201358.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1993_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jhep.2013.04.036","volume":"59","author":"C Fagundes","year":"2013","unstructured":"Fagundes C, Barreto R, Guevara M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol. 2013;59:474\u201381.","journal-title":"J Hepatol"},{"key":"1993_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/gutjnl-2011-301255","volume":"62","author":"CD Tsien","year":"2013","unstructured":"Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62:131\u20137.","journal-title":"Gut"},{"key":"1993_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1681\/ASN.2009080857","volume":"21","author":"T Berl","year":"2010","unstructured":"Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21:705\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"1993_CR9","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099\u2013112.","journal-title":"N Engl J Med"},{"key":"1993_CR10","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930\u201342.","journal-title":"N Engl J Med"},{"key":"1993_CR11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","volume":"57","author":"VE Torres","year":"2011","unstructured":"Torres VE, Meijer E, Bae KT, et al. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3\u20134 study. Am J Kidney Dis. 2011;57:692\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1993_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00535-017-1366-6","volume":"53","author":"Y Hiramine","year":"2018","unstructured":"Hiramine Y, Uojima H, Nakanishi H, et al. Response criteria of tolvaptan for the treatment of hepatic edema. J Gastroenterol. 2018;53:258\u201368.","journal-title":"J Gastroenterol"},{"key":"1993_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/hepr.12778","volume":"47","author":"Y Hiramine","year":"2017","unstructured":"Hiramine Y, Uto H, Imamura Y, et al. Efficacy of vasopressin V2 receptor antagonist tolvaptan in treatment of hepatic edema. Hepatol Res. 2017;47:542\u201357.","journal-title":"Hepatol Res"},{"key":"1993_CR14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/hepr.12826","volume":"47","author":"H Kawaratani","year":"2017","unstructured":"Kawaratani H, Fukui H, Moriya K, et al. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites. Hepatol Res. 2017;47:854\u201361.","journal-title":"Hepatol Res"},{"key":"1993_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/hepr.12822","volume":"47","author":"T Kogiso","year":"2017","unstructured":"Kogiso T, Yamamoto K, Kobayashi M, et al. Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites. Hepatol Res. 2017;47:835\u201344.","journal-title":"Hepatol Res"},{"key":"1993_CR16","doi-asserted-by":"publisher","first-page":"E311","DOI":"10.1111\/hepr.12988","volume":"48","author":"M Nakai","year":"2018","unstructured":"Nakai M, Ogawa K, Takeda R, et al. Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. Hepatol Res. 2018;48:E311\u20139.","journal-title":"Hepatol Res"},{"key":"1993_CR17","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.1111\/hepr.12716","volume":"47","author":"H Uojima","year":"2017","unstructured":"Uojima H, Kinbara T, Hidaka H, et al. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites. Hepatol Res. 2017;47:E14\u201321.","journal-title":"Hepatol Res"},{"key":"1993_CR18","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/jgh.14047","volume":"33","author":"M Atsukawa","year":"2018","unstructured":"Atsukawa M, Tsubota A, Kato K, et al. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. J Gastroenterol Hepatol. 2018;33:1256\u201363.","journal-title":"J Gastroenterol Hepatol"},{"key":"1993_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174649","volume":"12","author":"Y Komiyama","year":"2017","unstructured":"Komiyama Y, Kurosaki M, Nakanishi H, et al. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na\/K ratio. PLoS One. 2017;12: e0174649.","journal-title":"PLoS One"},{"key":"1993_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/hepr.12852","volume":"47","author":"I Sakaida","year":"2017","unstructured":"Sakaida I, Terai S, Kurosaki M, et al. Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: interim results of post-marketing surveillance of tolvaptan in liver cirrhosis (START study). Hepatol Res. 2017;47:1137\u201346.","journal-title":"Hepatol Res"},{"key":"1993_CR21","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s00535-020-01721-8","volume":"55","author":"M Nakai","year":"2020","unstructured":"Nakai M, Suda G, Kubo A, et al. Durable response without recurrence to tolvaptan improves long-term survival. J Gastroenterol. 2020;55:1150\u201361.","journal-title":"J Gastroenterol"},{"key":"1993_CR22","doi-asserted-by":"publisher","first-page":"8062","DOI":"10.3748\/wjg.v23.i45.8062","volume":"23","author":"H Uojima","year":"2017","unstructured":"Uojima H, Hidaka H, Nakayama T, et al. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: a randomized study. World J Gastroenterol. 2017;23:8062\u201372.","journal-title":"World J Gastroenterol"},{"key":"1993_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/432811a","volume":"432","author":"J Barasch","year":"2004","unstructured":"Barasch J, Mori K. Cell biology: iron thievery. Nature. 2004;432:811\u20133.","journal-title":"Nature"},{"key":"1993_CR24","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(05)74811-X","volume":"365","author":"J Mishra","year":"2005","unstructured":"Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. The Lancet. 2005;365:1231\u20138.","journal-title":"The Lancet"},{"key":"1993_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110527","volume":"9","author":"A Tsuchimoto","year":"2014","unstructured":"Tsuchimoto A, Shinke H, Uesugi M, et al. Urinary neutrophil gelatinase-associated lipocalin: a useful biomarker for tacrolimus-induced acute kidney injury in liver transplant patients. PLoS One. 2014;9: e110527.","journal-title":"PLoS One"},{"key":"1993_CR26","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","volume":"62","author":"P Angeli","year":"2015","unstructured":"Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the international club of ascites. J Hepatol. 2015;62:968\u201374.","journal-title":"J Hepatol"},{"key":"1993_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/hepr.13499","volume":"50","author":"M Ohara","year":"2020","unstructured":"Ohara M, Suda G, Kimura M, et al. Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. Hepatol Res. 2020;50:715\u201325.","journal-title":"Hepatol Res"},{"key":"1993_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1993_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693\u20139.","journal-title":"N Engl J Med"},{"key":"1993_CR30","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1053\/he.2000.5852","volume":"31","author":"M Malinchoc","year":"2000","unstructured":"Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864\u201371.","journal-title":"Hepatology"},{"key":"1993_CR31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/hep.21563","volume":"45","author":"PS Kamath","year":"2007","unstructured":"Kamath PS, Kim WR, Advanced Liver Disease Study G. The model for end-stage liver disease (MELD). Hepatology. 2007;45:797\u2013805.","journal-title":"Hepatology"},{"key":"1993_CR32","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa0801209","volume":"359","author":"WR Kim","year":"2008","unstructured":"Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018\u201326.","journal-title":"N Engl J Med"},{"key":"1993_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/jgh.14784","volume":"35","author":"I Bellos","year":"2020","unstructured":"Bellos I, Kontzoglou K, Perrea DN. Predictors of tolvaptan short-term response in patients with refractory ascites: a meta-analysis. J Gastroenterol Hepatol. 2020;35:182\u201391.","journal-title":"J Gastroenterol Hepatol"},{"key":"1993_CR34","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179\u201384.","journal-title":"Nephron Clin Pract"},{"key":"1993_CR35","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/ndt\/gfr006","volume":"26","author":"KM Schmidt-Ott","year":"2011","unstructured":"Schmidt-Ott KM. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury\u2013where do we stand today? Nephrol Dial Transplant. 2011;26:762\u20134.","journal-title":"Nephrol Dial Transplant"},{"key":"1993_CR36","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s00467-007-0601-4","volume":"22","author":"R Hirsch","year":"2007","unstructured":"Hirsch R, Dent C, Pfriem H, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol. 2007;22:2089\u201395.","journal-title":"Pediatr Nephrol"},{"key":"1993_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3109\/00365513.2013.860615","volume":"74","author":"C Liebetrau","year":"2014","unstructured":"Liebetrau C, Gaede L, Doerr O, et al. Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of contrast-induced nephropathy after percutaneous coronary intervention. Scand J Clin Lab Invest. 2014;74:81\u20138.","journal-title":"Scand J Clin Lab Invest"},{"key":"1993_CR38","doi-asserted-by":"publisher","first-page":"205435812093421","DOI":"10.1177\/2054358120934215","volume":"7","author":"BC Gomes","year":"2020","unstructured":"Gomes BC, Silva Junior JM, Tuon FF. Evaluation of urinary NGAL as a diagnostic tool for acute kidney injury in critically ill patients with infection: an original study. Can J Kidney Health Dis. 2020;7:2054358120934215.","journal-title":"Can J Kidney Health Dis"},{"key":"1993_CR39","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1097\/01.ASN.0000088027.54400.C6","volume":"14","author":"J Mishra","year":"2003","unstructured":"Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534\u201343.","journal-title":"J Am Soc Nephrol"},{"key":"1993_CR40","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1097\/01.ASN.0000145013.44578.45","volume":"15","author":"J Mishra","year":"2004","unstructured":"Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2004;15:3073\u201382.","journal-title":"J Am Soc Nephrol"},{"key":"1993_CR41","doi-asserted-by":"publisher","first-page":"810","DOI":"10.7326\/0003-4819-148-11-200806030-00003","volume":"148","author":"TL Nickolas","year":"2008","unstructured":"Nickolas TL, O\u2019Rourke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med. 2008;148:810\u20139.","journal-title":"Ann Intern Med"},{"key":"1993_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32799","author":"C Gambino","year":"2022","unstructured":"Gambino C, Piano S, Stenico M, et al. Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and AKI. Hepatology. 2022. https:\/\/doi.org\/10.1002\/hep.32799.","journal-title":"Hepatology"},{"key":"1993_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jhep.2016.03.002","volume":"65","author":"X Ariza","year":"2016","unstructured":"Ariza X, Graupera I, Coll M, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J Hepatol. 2016;65:57\u201365.","journal-title":"J Hepatol"},{"key":"1993_CR44","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3748\/wjg.v24.i21.2300","volume":"24","author":"QQ Jiang","year":"2018","unstructured":"Jiang QQ, Han MF, Ma K, et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis. World J Gastroenterol. 2018;24:2300\u201310.","journal-title":"World J Gastroenterol"},{"key":"1993_CR45","doi-asserted-by":"publisher","first-page":"7962","DOI":"10.1038\/s41598-018-26226-6","volume":"8","author":"L Lei","year":"2018","unstructured":"Lei L, Li LP, Zeng Z, et al. Value of urinary KIM-1 and NGAL combined with serum Cys C for predicting acute kidney injury secondary to decompensated cirrhosis. Sci Rep. 2018;8:7962.","journal-title":"Sci Rep"},{"key":"1993_CR46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00535-020-01727-2","volume":"56","author":"Y Hiramine","year":"2021","unstructured":"Hiramine Y, Uto H, Mawatari S, et al. Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites. J Gastroenterol. 2021;56:54\u201366.","journal-title":"J Gastroenterol"},{"key":"1993_CR47","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1253\/circj.CJ-16-1122","volume":"81","author":"S Tamaki","year":"2017","unstructured":"Tamaki S, Sato Y, Yamada T, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure and preserved left ventricular ejection fraction- prospective randomized controlled study. Circ J. 2017;81:740\u20137.","journal-title":"Circ J"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-01993-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-01993-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-01993-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T14:04:10Z","timestamp":1687961050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-023-01993-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1993"],"URL":"https:\/\/doi.org\/10.1007\/s00535-023-01993-w","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"type":"print","value":"0944-1174"},{"type":"electronic","value":"1435-5922"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Professor Naoya Sakamoto received lecture fees from Bristol Myers Squibb and Pharmaceutical K. K., grants and endowments from MSD K. K and Chugai Pharmaceutical Co., Ltd. and a research grant from Gilead Sciences Inc. Professor Kenichi Morikawa received research grants from Gilead Sciences, Inc., Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd. Professor Goki Suda has received research grants from Bristol Myers Squibb. The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}